Table 2.
Comparison of characteristics between patients that did (responders) and did not (non-responders) have improvement in respiratory parameters at seven days following tocilizumab therapy.
| IV Group (n = 65) |
SC Group (n = 60) |
|||
|---|---|---|---|---|
| Responders (n = 34) | Non-responders (n = 31) | Responders (n = 17) | Non-responders (n = 43) | |
| Age, years, mean ± SD | 58.4 ± 17.0 | 59.4 ± 19.0 | 53 ± 17.6 | 58.9 ± 13.7 |
| Sex, No. (%), female | 12 (35%) | 15 (48%) | 3 (18%) | 12 (29%) |
| Race, No. (%), African American | 21 (59%) | 22 (52%) | 13 (76%) | 31 (73%) |
| Body mass index kg/m2, mean ± SD | 33.4 ± 11.1 | 31.4 ± 10.1 | 34.1 ± 9.5 | 32.6 ± 10.4 |
| Comorbidities | ||||
| Diabetes, No. (%) | 12 (35%) | 13 (42%) | 4 (24%) | 25 (58%)a |
| Hypertension, No. (%) | 24 (71%) | 19 (61%) | 7 (41%) | 28 (65%) |
| Renal disease, No. (%) | 1 (3%) | 6 (19%)a | 2 (12%) | 4 (9%) |
| Duration of symptoms, days, mean ± SD | 11.3 ± 12.2 | 10.6 ± 6.0 | 14.6 ± 8.2 | 13.4 ± 7.3 |
| C-reactive protein mg/L, mean ± SD | 166 ± 90 | 224 ± 95a | 175 ± 97.2 | 223 ± 172 |
| D-dimers ng/mL, mean ± SD | 6509 ± 14,383 | 10,332 ± 17,825 | 5712 ± 14,719 | 13,283 ± 19,549 |
| Ferritin ng/mL, mean ± SD | 1051 ± 800 | 1365 ± 570 | 1298 ± 619 | 1420 ± 783 |
| Interleukin-6 pg/mL, mean ± SD | 289 ± 628 | 391 ± 691 | 149 ± 222 | 115 ± 131 |
| Lactic acid dehydrogenase U/L, mean ± SD | 647 ± 255 | 758 ± 383 | 608 ± 385 | 732 ± 288 |
| Procalcitonin ng/mL, mean ± SD | 5.44 ± 19.4 | 7.31 ± 18.6 | 2.36 ± 5.93 | 3.17 ± 8.9 |
a
P≤0.05 comparing values between the two groups.